Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
Sponsor: Beijing Tiantan Hospital
Summary
Primary endpoint 1. three-year disease-free survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Health-related quality of life measured by PedsQL 4.0 and SF-36 Second endpoint 1. three-year overall survival of patients with localized basal ganglia germ cell tumors receiving whole-ventricle irradiation 2. Adverse effects of chemoradiotherapy measured by NCI CTCAE 5.0
Official title: The Efficacy of Whole-ventricle Irradiation Plus Primary Boost in Patients With Localized Basal Ganglia Germ Cell Tumors: Prospective Phase II Study
Key Details
Gender
All
Age Range
3 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2021-09-15
Completion Date
2026-10-31
Last Updated
2021-11-18
Healthy Volunteers
No
Interventions
Whole-ventricle irradiation
Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
Carboplatin/etoposide
Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
Ifosfamide/cisplatin/etoposide
Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
Second-look surgery
Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
Locations (1)
Beijing Tiantan Hospital
Beijing, China